Transforming Medical Technology: The Launch of the Innovative Devices Access Pathway in the UK

By HEOR Staff Writer

September 20, 2023

A New Era of Medical Innovation

The Department of Health and Social Care (DHSC), Health Technology Wales (HTW), the Medicines and Healthcare products Regulatory Agency (MHRA), and several other health organizations have launched the Innovative Devices Access Pathway (IDAP) pilot. This new pathway, backed by £10 million of government funding, aims to fast-track patient access to innovative technologies by providing comprehensive support and advice to innovators and manufacturers.

A Pathway Paved with Potential

The IDAP is more than just a funding program. It’s a vision for the future of healthcare in the UK. The pathway aims to support the rapid development of innovative technologies that can be introduced into the National Health Service (NHS) to address unmet clinical needs. This is not just about getting new products to market quickly, but also ensuring they meet the highest standards of safety, quality, and effectiveness.

The pilot phase of the IDAP has now been launched, with innovators invited to submit Expressions of Interest for access into the pathway. Successful applicants will receive a range of support, including the development of a targeted product roadmap, system navigation advice, and support with Health Technology Assessments (HTA) for product realization and adoption.

The IDAP is open to both commercial and non-commercial innovators of medical technology in the UK and abroad. The submissions for the pilot phase opened on 19 September 2023 and will close on 29 October 2023. The future of healthcare is here, and it’s innovative, inclusive, and incredibly exciting.

Reference url

Recent Posts

Dutch Medicine Access Delay
Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

By João L. Carapinha

June 10, 2026

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...
Factor XIa Inhibition Stroke
Advancements in Factor XIa Inhibition Stroke Prevention Through Asundexian

By HEOR Staff Writer

June 10, 2026

The European Medicines Agency has accepted Bayer’s marketing authorization application for asundexian, marking a major advance in Factor XIa Inhibition Stroke prevention. This oral agent selectively interrupts a key step in the coagulation cascade to reduce recurrent ischemic stroke risk in adult...
clinical skill assessment
Transforming Clinical Skill Assessment with Intelligent Evaluation Systems

By HEOR Staff Writer

June 10, 2026

Clinical skill assessment has long been hampered by subjective judgments and variability among examiners. A novel unified intelligent framework replaces these manual observations with contrastive learning to deliver objective, trace...